Inventor · disambiguated record
Baltazar Gomez-Mancilla
Also filed as: GOMEZ-MANCILLA BALTAZAR
11 granted patents·19 pending applications·68 citations·filing 1998–2022
87Inventor score
Top patents by PatentIndex Score
30 records- 0185US8703809B2Combination productsGOMEZ-MANCILLA BALTAZAR·Filed 2009·Granted Apr 22, 2014·15 cites·2 claims
- 0273US12215387B2Biomarker predictive of responsiveness to alpha 7 nicotinic acetylcholine receptor activator treatmentNOVARTIS AG·Filed 2022·Granted Feb 4, 2025·0 cites·20 claims
- 0372US11096916B2Use of nicotinic acetylcholine receptor alpha 7 activatorsNOVARTIS AG·Filed 2019·Granted Aug 24, 2021·0 cites·6 claims
- 0472US6001861AUse of pramipexole in the treatment of restless legs syndromeUPJOHN CO·Filed 1998·Granted Dec 14, 1999·36 cites·4 claims
- 0569US12201612B2Use of mavoglurant in the reduction of alcohol use or in preventing relapse into alcohol useNOVARTIS AG·Filed 2018·Granted Jan 21, 2025·1 cites·13 claims
- 0669US11878001B2Use of mavoglurant in the reduction of cocaine use or in preventing relapse into cocaine useNOVARTIS AG·Filed 2018·Granted Jan 23, 2024·1 cites·13 claims
- 0767US9828642B2Biomarkers predictive of responsiveness to alpha 7 nicotinic acetylcholine receptor activator treatmentNOVARTIS AG·Filed 2015·Granted Nov 28, 2017·1 cites·11 claims
- 0866US2022211679A1Alpha 7 nicotinic acetylcholine receptor agonistsNOVARTIS AG·Filed 2022·Application pending·0 cites
- 0965US2021338621A1Use of nicotinic acetylcholine receptor alpha 7 activatorsNOVARTIS AG·Filed 2021·Application pending·0 cites
- 1062US11359241B2Biomarkers predictive of responsiveness to alpha 7 nicotinic acetylcholine receptor activator treatmentNOVARTIS AG·Filed 2017·Granted Jun 14, 2022·0 cites·8 claims
- 1156US2024082215A1Use of mglur5 antagonists for treating gambling disorderNOVARTIS AG·Filed 2021·Application pending·0 cites
- 1256US2024050408A1Use of mglur5 antagonists for treating amphetamine addictionNOVARTIS AG·Filed 2021·Application pending·0 cites
- 1355US2023270720A1Mavoglurant, a mglur5 antagonist, for use in the treatment in the reduction of opioid useNOVARTIS AG·Filed 2021·Application pending·0 cites
- 1451US2010249136A1Organic compoundsUMBRICHT DANIEL·Filed 2008·Application pending·0 cites
- 1550US2015313884A1Use of alpha 7 nicotinic acetylcholine receptor agonistsNOVARTIS AG·Filed 2015·Application pending·0 cites
- 1649US2011212980A1Combinations for the treatment of migraineNOVARTIS AG·Filed 2009·Application pending·0 cites
- 1749US2022175793A1The use of an mglur5 antagonist for treating opioid analgesic toleranceNOVARTIS AG·Filed 2020·Application pending·0 cites
- 1848US2003045539A1Cabergoline and pramipexole: new uses and combinationsFiled 2002·Application pending·0 cites
- 1948US2024216369A1The use of a splicing modulator for a treatment slowing progression of huntington's diseaseNOVARTIS AG·Filed 2020·Application pending·0 cites
- 2047US2010035251A1BioMarkers for the Progression of Alzheimer's DiseaseHE YUNSHENG·Filed 2007·Application pending·0 cites
- 2146US2014194423A1Combination productsGOMEZ-MANCILLA BALTAZAR·Filed 2014·Application pending·0 cites
- 2246US2024041853A1Dosage regimen for a nr2b-nmda receptor nam for the treatment of depressionNOVARTIS AG·Filed 2021·Application pending·0 cites
- 2345US6503920B1Cabergoline and pramipexole: new uses and combinationsUPJOHN CO·Filed 1999·Granted Jan 7, 2003·6 cites·10 claims
- 2444US10537539B2Use of nicotinic acetylcholine receptor alpha 7 activatorsDI PAOLO THERESE·Filed 2010·Granted Jan 21, 2020·0 cites·5 claims
- 2544US6194445B1Use of pramipexole in the treatment of restless legs syndromeUPJOHN CO·Filed 1999·Granted Feb 27, 2001·8 cites·1 claims
- 2642US2012157464A1Use of azabicycloalkyl derivatives or pyrrolidine-2-one derivatives for the treatment or prevention of ataxiaFEUERBACH DOMINIK·Filed 2010·Application pending·0 cites
- 2735US2015272929A1Organic compoundsUMBRICHT DANIEL·Filed 2015·Application pending·0 cites
- 2835US2014171448A1Use of nicotinic acetylcholine receptor alpha 7 activatorsFEUERBACH DOMINIK·Filed 2012·Application pending·0 cites
- 2933US2013052644A1Predictive Markers Useful in the Treatment of Fragile X Syndrome (FXS)GOMEZ-MANCILLA BALTAZAR·Filed 2011·Application pending·0 cites
- 3028US2014228398A1COMBINATIONS OF ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVATORS AND mGluR5 ANTAGONISTS FOR USE IN DOPAMINE INDUCED DYSKINESIA IN PARKINSON'S DISEASEDI PAOLO THERESE·Filed 2012·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Baltazar Gomez-Mancilla files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →